In a significant development for women’s health, the longstanding term polycystic ovary syndrome (PCOS) has been officially rebranded as polyendocrine metabolic ovarian syndrome (PMOS). This change, announced at the European Congress of Endocrinology in Prague, follows over a decade of advocacy and collaboration among medical professionals and patient groups. The new terminology aims to capture the multifaceted nature of the condition, which affects approximately 170 million women worldwide.
A New Chapter for Women Affected by PMOS
The renaming of PCOS to PMOS marks a pivotal moment for many women who have grappled with the misconceptions surrounding their diagnosis. According to Professor Helena Teede, director of Melbourne’s Monash Centre for Health Research and Implementation, the previous term “polycystic” was misleading and contributed to delays in diagnosis and treatment. “The term didn’t adequately represent the multi-system burden that individuals face,” she explained during the announcement. “We hope PMOS will lead to a more comprehensive understanding of the hormonal and metabolic challenges that come with this condition.”
Women like Maddy Mavrikis, who shared her personal experience with the Guardian, have long felt the weight of this misunderstanding. Diagnosed at just 15, Mavrikis was told she might never have children—a statement that turned out to be incorrect. “I never had cysts on my ovaries, so I questioned why I was labelled with that name,” she recalled, illustrating the confusion that the old terminology created.
Addressing Misconceptions and Providing Clarity
The symptoms of PMOS extend far beyond reproductive health. The condition is associated with hormonal imbalances that can lead to a range of issues including insulin resistance, acne, and excessive hair growth. The new name is designed to reflect this broader impact, acknowledging that PMOS encompasses metabolic health and increases the risk of diabetes and cardiovascular disease.
The rebranding has garnered support from a diverse array of stakeholders, with 56 medical and patient societies participating in the decision-making process. This collaborative approach was necessary to ensure that the new name resonates globally and is embraced across various regions. Teede emphasised that it was crucial to consider the voices of those living with the condition, stating, “Patients initiated this change because they wanted their experiences to be validated. Their suffering under the old name was significant.”
Patients at the Forefront of Change
The journey towards renaming PCOS has been long and fraught with challenges. Discussions about the need for a new name date back to 1995, with various forums advocating for change since then. The recent decision was the culmination of extensive surveys and workshops aimed at determining a name that accurately reflects the condition while avoiding the stigma associated with reproductive health issues.
Lorna Berry, a long-time advocate for better education on PMOS, played a crucial role in the workshops that led to the name change. She noted that many participants were initially hesitant about removing the term “reproductive” from the name due to its clinical accuracy. However, Berry successfully highlighted that many patients preferred a name that would not carry the societal stigma often associated with reproductive conditions.
Looking Ahead: Implementation and Awareness
As the healthcare community prepares for the full adoption of the PMOS terminology, the new name will be incorporated into international guidelines for managing the condition by 2028. This transition period will allow for the necessary education and resources to be developed, ensuring that both patients and healthcare providers understand the implications of the change.
Mavrikis expressed hope that the new name will foster a greater awareness of PMOS, leading to improved care and understanding from medical professionals. “Changing the name indicates that they are beginning to pay attention,” she remarked, reflecting a collective aspiration for more nuanced and comprehensive treatment options for all those affected.
Why it Matters
The renaming of PCOS to PMOS not only represents a shift in medical terminology but also signifies a broader recognition of women’s health issues that have long been overlooked. By embracing a name that encapsulates the complexity of the condition, healthcare providers can potentially enhance diagnostic accuracy and treatment outcomes. This change is a testament to the power of patient advocacy and the importance of listening to the voices of those living with chronic conditions. For millions, the hope is that PMOS will lead to more informed healthcare practices, ultimately improving the quality of life for those affected.